Episode Details

Host Jessica Seidelman, MD has an in-depth discussion with Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. in the opening episode of this 3-part series. They discuss why PJI infections are so difficult to treat, and advances in antimicrobial agents in the pipeline. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

Listen Now